EDX

The healthcare sector is experiencing a remarkable transformation driven by advancements in technology and an increasing focus on personalised medicine. Among the significant trends shaping the industry are the integration

Cambridge-based EDX Medical is set to introduce a diagnostic tool in the UK aimed at identifying patients’ risk of developing hereditary cancer. This tool, which remains unnamed, focuses on germline

Nucleic acid-based biomarkers are integral to precision medicine, acting as indicators for a range of biological states, from disease predisposition to therapeutic effectiveness. Their application in numerous diseases necessitates thorough

EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable

https://www.youtube.com/watch?v=EIoBQl90Xcg EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making,

Guardant Health, Inc. (NASDAQ: GH), a precision oncology company, has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746) for its Guardant360® CDx blood test. This certification,

The Guardant360 CDx blood test has received certification from TÜV SÜD Product Service under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746) for tumour mutation profiling in patients with